• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种研究抗体聚集及聚集抑制的便捷策略:表征与模拟

A Convenient Strategy for Studying Antibody Aggregation and Inhibition of Aggregation: Characterization and Simulation.

作者信息

Guo Yibo, Chen Xi, Fang Guchen, Cao Xuejun, Wan Junfen

机构信息

State Key Laboratory of Bioreactor Engineering, Department of Bioengineering, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.

出版信息

Pharmaceutics. 2025 Apr 19;17(4):534. doi: 10.3390/pharmaceutics17040534.

DOI:10.3390/pharmaceutics17040534
PMID:40284529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12030238/
Abstract

Protein aggregation, particularly the aggregation of antibody-based drugs, has long been a significant challenge in downstream processes and formulation. While the inhibitory effects of excipients on aggregation have been extensively studied using early experimental characterization methods, complete formulation research requires significant amounts of antibodies and time, resulting in high research costs. This study proposed a quick and small-scale position-restrained simulation method which elucidated the mechanism of the reversible self-association (RSA) of antibodies and the influence of excipients on RSA under different conditions. We also validated the rationality of rapid and small-scale simulations through long-term (>1 μs) and large-scale (>1,000,000 atoms) simulations. : Through combing with simple stability characterization, the effects of different excipients on monomer residual content and the trend shown with concentration changes after thermal incubation were found to be similar to those observed in the simulations. Additionally, the formulation proposed by the simulations was validated using experimental characterization. : Simulations and experiments revealed the mechanism and showed consistent trends, providing better understanding for aggregation research.

摘要

蛋白质聚集,尤其是基于抗体的药物聚集,长期以来一直是下游工艺和制剂中的重大挑战。虽然使用早期实验表征方法对辅料对聚集的抑制作用进行了广泛研究,但完整的制剂研究需要大量抗体和时间,导致研究成本高昂。本研究提出了一种快速且小规模的位置受限模拟方法,该方法阐明了抗体可逆自聚集(RSA)的机制以及不同条件下辅料对RSA的影响。我们还通过长期(>1 μs)和大规模(>1,000,000个原子)模拟验证了快速和小规模模拟的合理性。通过与简单的稳定性表征相结合,发现不同辅料对单体残留含量的影响以及热孵育后随浓度变化呈现的趋势与模拟中观察到的相似。此外,模拟提出的制剂通过实验表征进行了验证。模拟和实验揭示了机制并呈现出一致的趋势,为聚集研究提供了更好的理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/a6b2ac304524/pharmaceutics-17-00534-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/89bea6fac0ec/pharmaceutics-17-00534-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/fbc6dcf3a991/pharmaceutics-17-00534-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/7de0eccaeb8f/pharmaceutics-17-00534-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/ce18e2ded6ba/pharmaceutics-17-00534-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/eac8817534bb/pharmaceutics-17-00534-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/0ee124c6575b/pharmaceutics-17-00534-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/d770854d46b6/pharmaceutics-17-00534-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/12dda8450d73/pharmaceutics-17-00534-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/a6b2ac304524/pharmaceutics-17-00534-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/89bea6fac0ec/pharmaceutics-17-00534-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/fbc6dcf3a991/pharmaceutics-17-00534-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/7de0eccaeb8f/pharmaceutics-17-00534-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/ce18e2ded6ba/pharmaceutics-17-00534-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/eac8817534bb/pharmaceutics-17-00534-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/0ee124c6575b/pharmaceutics-17-00534-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/d770854d46b6/pharmaceutics-17-00534-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/12dda8450d73/pharmaceutics-17-00534-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1a/12030238/a6b2ac304524/pharmaceutics-17-00534-g009.jpg

相似文献

1
A Convenient Strategy for Studying Antibody Aggregation and Inhibition of Aggregation: Characterization and Simulation.一种研究抗体聚集及聚集抑制的便捷策略:表征与模拟
Pharmaceutics. 2025 Apr 19;17(4):534. doi: 10.3390/pharmaceutics17040534.
2
Molecular Dynamics Simulations Reveal How Competing Protein-Surface Interactions for Glycine, Citrate, and Water Modulate Stability in Antibody Fragment Formulations.分子动力学模拟揭示了甘氨酸、柠檬酸盐和水与蛋白质表面相互作用的竞争如何调节抗体片段制剂的稳定性。
Mol Pharm. 2024 Nov 4;21(11):5497-5509. doi: 10.1021/acs.molpharmaceut.4c00332. Epub 2024 Oct 21.
3
Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody.氢交换质谱揭示了IgG1单克隆抗体可逆自缔合过程中的蛋白质界面和远距离动态偶联效应。
MAbs. 2015;7(3):525-39. doi: 10.1080/19420862.2015.1029217.
4
Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate.解析辅料稳定治疗性蛋白的机制:精氨酸和谷氨酸两种单克隆抗体的案例研究
MAbs. 2024 Jan-Dec;16(1):2427771. doi: 10.1080/19420862.2024.2427771. Epub 2024 Nov 14.
5
Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).大分子拥挤现象:化学与物理邂逅生物学(瑞士阿斯科纳,2012年6月10日至14日)
Phys Biol. 2013 Aug;10(4):040301. doi: 10.1088/1478-3975/10/4/040301. Epub 2013 Aug 2.
6
Molecular computations of preferential interactions of proline, arginine.HCl, and NaCl with IgG1 antibodies and their impact on aggregation and viscosity.脯氨酸、精氨酸盐酸盐和 NaCl 与 IgG1 抗体优先相互作用的分子计算及其对聚集和粘度的影响。
MAbs. 2020 Jan-Dec;12(1):1816312. doi: 10.1080/19420862.2020.1816312.
7
Effects of temperature and osmolytes on competing degradation routes for an IgG1 antibody.温度和渗透剂对 IgG1 抗体竞争降解途径的影响。
J Pharm Sci. 2013 Oct;102(10):3556-66. doi: 10.1002/jps.23668. Epub 2013 Jul 19.
8
Freezing-induced protein aggregation in a bispecific antibody: Characterization and mechanistic insights.双特异性抗体中冷冻诱导的蛋白质聚集:表征与机理洞察
J Pharm Sci. 2025 May;114(5):103711. doi: 10.1016/j.xphs.2025.103711. Epub 2025 Feb 27.
9
Predictive Model Building for Aggregation Kinetics Based on Molecular Dynamics Simulations of an Antibody Fragment.基于抗体片段分子动力学模拟的聚集动力学预测模型构建。
Mol Pharm. 2024 Nov 4;21(11):5827-5841. doi: 10.1021/acs.molpharmaceut.4c00859. Epub 2024 Sep 30.
10
Selective Stabilization and Destabilization of Protein Domains in Tissue-Type Plasminogen Activator Using Formulation Excipients.使用配方辅料选择性稳定和不稳定组织型纤溶酶原激活物的蛋白质结构域。
Mol Pharm. 2019 Feb 4;16(2):744-755. doi: 10.1021/acs.molpharmaceut.8b01024. Epub 2019 Jan 9.

本文引用的文献

1
AggreProt: a web server for predicting and engineering aggregation prone regions in proteins.AggreProt:一个用于预测和设计蛋白质中易于聚集区域的网络服务器。
Nucleic Acids Res. 2024 Jul 5;52(W1):W159-W169. doi: 10.1093/nar/gkae420.
2
Mechanism of Protein Aggregation Inhibition by Arginine: Blockage of Anionic Side Chains Favors Unproductive Encounter Complexes.精氨酸抑制蛋白质聚集的机制:阻断阴离子侧链有利于非生产性碰撞复合物。
J Am Chem Soc. 2024 Mar 27;146(12):8394-8406. doi: 10.1021/jacs.3c14180. Epub 2024 Mar 13.
3
Sugar Molecules Inhibit Insulin Aggregation: A Decisive Role Being Played by the Protein Solvation Energetics.
糖分子抑制胰岛素聚集:蛋白质溶剂化能起着决定性作用。
J Phys Chem B. 2023 Oct 19;127(41):8825-8832. doi: 10.1021/acs.jpcb.3c04765. Epub 2023 Oct 10.
4
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements.癌症治疗中的双特异性抗体:靶点选择与监管要求
Acta Pharm Sin B. 2023 Sep;13(9):3583-3597. doi: 10.1016/j.apsb.2023.05.023. Epub 2023 May 23.
5
L-lysine moderates thermal aggregation of coconut proteins induced by thermal treatment.L-赖氨酸可调节热加工诱导的椰子蛋白的热聚集。
Sci Rep. 2023 Aug 16;13(1):13310. doi: 10.1038/s41598-023-38758-7.
6
Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles.在β链受体界面处对噬菌体展示的白细胞介素-2进行分子重塑,以获得具有改善开发特性的强效超激动剂。
Commun Biol. 2023 Aug 9;6(1):828. doi: 10.1038/s42003-023-05188-0.
7
Advances in the understanding of protein misfolding and aggregation through molecular dynamics simulation.通过分子动力学模拟深入了解蛋白质错误折叠和聚集。
Prog Biophys Mol Biol. 2022 Nov;175:31-48. doi: 10.1016/j.pbiomolbio.2022.08.007. Epub 2022 Aug 28.
8
Inhibition of Aβ Peptide Aggregation by Small Molecules and Their Permeation through POPC Lipid Bilayer: Insight from Molecular Dynamics Simulation Study.小分子抑制 Aβ 肽聚集及其通过 POPC 脂双层的渗透:分子动力学模拟研究的见解。
J Chem Inf Model. 2022 Nov 14;62(21):5193-5207. doi: 10.1021/acs.jcim.1c01366. Epub 2022 Mar 20.
9
Computational models for studying physical instabilities in high concentration biotherapeutic formulations.用于研究高浓度生物治疗制剂物理不稳定性的计算模型。
MAbs. 2022 Jan-Dec;14(1):2044744. doi: 10.1080/19420862.2022.2044744.
10
Nucleation in Protein Aggregation in Biotherapeutic Development: A look into the Heart of the Event.生物治疗开发中的蛋白聚集成核:洞察事件核心
J Pharm Sci. 2022 Apr;111(4):951-959. doi: 10.1016/j.xphs.2022.01.017. Epub 2022 Jan 31.